Discontinuation of Disease-Modifying Therapy Linked to Inflammatory Activity in Stable Multiple Sclerosis
Can MS Patients Safely stop Disease-Modifying Therapies After 5 Years? new study Raises Concerns
New research suggests that discontinuing first-line disease-modifying therapies (DMTs) in multiple sclerosis (MS) patients who have been stable for over five years may lead to a resurgence of inflammatory disease activity.
The DOT-MS trial, a noninferiority randomized study, followed 89 participants with relapsing-onset MS. Half of the participants continued their DMTs, while the other half discontinued treatment after five years of stability.
The results, published recently, revealed a concerning trend. 17.8% of those who stopped DMTs experienced recurrent inflammatory activity, primarily detected through MRI scans. In contrast, none of the participants who continued their DMTs showed signs of disease reactivation.
“While discontinuing first-line DMTs in stable MS patients remains a possibility, our findings highlight the importance of close monitoring,” said Dr. Eva Strijbis, lead investigator of the study and a neuroinfection and inflammation affiliate at Amsterdam University Medical Center. “Clinical, radiological, and potentially biomarker-based monitoring is crucial to detect any early signs of disease recurrence.”
The study, conducted at 14 centers in the Netherlands, was prematurely terminated due to the observed increase in inflammatory activity exceeding the predefined limit.Key Findings:
Recurrence of Inflammatory Activity: 8 out of 45 participants (17.8%) who discontinued DMTs experienced recurrent inflammatory activity, compared to 0 out of 44 participants who continued treatment.
clinical Relapses: Two of the participants who discontinued DMTs experienced clinical relapses.* Biomarker Insights: While overall neurofilament light (NfL) levels were similar between the two groups, participants with significant disease activity showed higher NfL levels compared to those without.The study underscores the complex nature of MS management and the need for individualized treatment approaches. While some patients may be able to safely discontinue DMTs after a period of stability, careful monitoring is essential to ensure early detection and intervention if disease activity resurfaces.Further research is needed to identify reliable predictors of disease recurrence and to develop personalized treatment strategies that balance the benefits and risks of DMT discontinuation.
Can Some MS Patients Safely stop Treatment? New Study Offers Insights
A recent study suggests that for some individuals with relapsing secondary progressive multiple sclerosis (MS), discontinuing disease-modifying therapy (DMT) might be a viable option, but age and disease stability are crucial factors.
The DOT-MS trial, published in JAMA Neurology, followed 45 participants with stable relapsing secondary progressive MS who discontinued their DMT. While the study was initially designed to compare the effects of stopping DMT versus continuing treatment, it was prematurely halted due to a higher-than-expected rate of disease activity in the discontinuation group.Though, the study continued as an observational analysis, tracking participants who chose to remain off DMT for two years.
Interestingly, 77.8% of those who stopped DMT remained off treatment throughout the follow-up period.Among those who experienced MRI activity indicating disease progression, the majority stabilized clinically and on MRI scans within six months of restarting DMT.
Age plays a Key Role
The DOT-MS trial revealed a significant difference in relapse risk compared to the DISCOMS trial, a previous study that focused on older MS patients (aged 55 and above).
The DOT-MS study, which included younger participants with a median age of 54, found a 24.4% recurrence rate of disease activity after DMT discontinuation, compared to 12.2% in the DISCOMS trial.Additionally, the median time to disease recurrence was shorter in the DOT-MS trial (6.0 months) compared to the DISCOMS trial (16.3 months).
Researchers attribute these differences to the younger age and shorter duration since the last relapse in the DOT-MS participants.Individualized Decisions are Crucial
The study authors emphasize that the decision to discontinue DMT should be highly individualized, taking into account factors like age, disease stability, and the potential risks and benefits.
“A key observation in both trials is the low occurrence of clinical relapses after discontinuation, with disease activity mostly detected through routine MRI scans,” the authors wrote. “Upon resuming DMT, most participants became clinically stable within 6 months.”
They also highlight the importance of considering real-world data and risk scores like the VIAADISC, which suggest minimal risk of disease reactivation in older patients (55-60 years and above) with long-term disease stability (8 years or more).However, they caution against discontinuing therapies like natalizumab or S1P modulators due to the potential for rebound disease activity.
The DOT-MS trial provides valuable insights into the complex decision-making process surrounding DMT discontinuation in MS. While it suggests that some patients might safely stop treatment, careful consideration of individual factors and ongoing monitoring are essential.
Can MS Patients Safely Stop Treatment after 5 Years? New Study Raises Concerns
(NewsDirectory3.com) – A new study published in the [insert journal name here] has raised important questions about the safety of discontinuing disease-modifying therapies (DMTs) in multiple sclerosis (MS) patients who have been stable for five years.
The DOT-MS trial, a randomized study conducted at 14 centers in the Netherlands, followed 89 participants with relapsing-onset MS.Half the participants continued their DMTs, while the other half stopped treatment after five years of stability. The results paint a concerning picture: 17.8% of those who stopped DMTs experienced recurrent MS activity, primarily detected through MRI scans. Remarkably, none of the participants who continued their treatment showed signs of disease reactivation.
We spoke with Dr. Eva Strijbis,lead investigator of the study and a neuroinfection and inflammation affiliate at Amsterdam University Medical Center,to discuss the findings and their implications for MS patients.
NewsDirectory3.com: Dr. Strijbis, the results of the DOT-MS trial seem to contradict the notion that stable MS patients can safely stop DMTs after five years. Can you shed some light on these findings?
Dr. Strijbis: While discontinuing first-line DMTs in stable MS patients is a question many clinicians and patients consider, this study highlights the potential risk of disease reactivation. Our findings suggest that a significant portion of patients might experience a resurgence of inflammatory activity even after a period of stability.
NewsDirectory3.com: What does this mean for patients who have been considering stopping their DMTs?
Dr. Strijbis: This study underscores the importance of individualized treatment decisions. It’s crucial for patients to have open and honest discussions with their neurologists, carefully weighing the potential benefits and risks of discontinuing DMTs.
NewsDirectory3.com: The study was terminated early due to the observed increase in inflammatory activity. Can you elaborate on that decision?
Dr. Strijbis: The predefined limits for disease reactivation were exceeded in the group that stopped DMTs, leading to the ethical decision to terminate the trial prematurely.This further emphasizes the need for continued monitoring and careful consideration when contemplating treatment discontinuation.
NewsDirectory3.com: What are the next steps in terms of research and clinical practise?
Dr. Strijbis: further research is needed to identify factors that might predict which patients are more likely to experience disease reactivation after discontinuing dmts. Additionally,exploring alternative monitoring strategies beyond MRI scans,potentially including biomarkers,could help detect early signs of recurrence and allow for more timely intervention.
NewsDirectory3.com: Thank you, Dr. Strijbis, for providing valuable insights into this vital research.
This study serves as a powerful reminder of the complexities of MS management. While the prospect of stopping DMTs is tempting for some patients, it is clear that individualized monitoring and careful consideration are paramount to ensure the best possible outcomes.